HE@Cam seminar: Christian Hill - Patient Access Scheme, Managed Access Agreement and their influence on the approval trends of new medicines, devices and diagnostics

Add to your list(s) Download to your calendar using vCal

• Christian Hill - CEO, MAP Biopharma
• Monday 11 June 2018, 15:00-16:00
• Clinical School - Seminar room 10.

If you have a question about this talk, please contact David Wastlund.

Health Economics @ Cambridge presents Christian Hill, CEO at MAP Biopharma, for a seminar on Patient Access Scheme, Managed Access Agreements and their influence on the approval trends of new medicines, devices and diagnostics.

Information can also be found here

About the seminar: The role of market access is pivotal to ensure rapid and maintained access to medicines, devices and diagnostics to all appropriate patients who would benefit from treatment at the right price. Approval trends have shown to be greatly influenced by the introduction of Patient Access Schemes (PAS) and Managed Access Arrangements (MAA).

Changes to the regulatory landscape has allowed bodies such as NICE to issue guidance on technologies with an evidence base that is smaller or earlier in its evolution than has previously been the case. This has allowed patient access to certain interventions earlier, such as through the EMA ’s ‘Adaptive Pathways’ scheme. However, these methods will often have greater uncertainly regarding the clinical and cost-effectiveness at the point of decision making.

PAS are agreements reached by life sciences companies, reducing cost to the NHS , enabling patients to access cost-effective and innovative interventions. MAAs are increasingly introduced when conclusions on reimbursement cannot be made due to uncertainties in the clinical evidence and/or financial impact of an intervention and are designed to reduce the cost, in particular with orphans, ultra-orphans and cancer drugs. The same principles are beginning to be used with devices and diagnostics.

Christian Hill: Christian is a seasoned Market Access professional with over 18 years of experience in the International Biotech and Pharmaceutical industry. He has been involved in over 50 HTAs across Europe and has built up a strong network of key influencers including EU and national agencies. Prior to co-founding MAP in 2012, he led market access teams and submissions at InterMune, Gilead, Pfizer and Genzyme on a very broad range of products and disease areas from chronic disease to ultra-orphan indications.

Christian is a member of the Steering Group of EMIG (Ethical Medicines Industry Group) in the UK and Ireland; he is also a member of the Board of EUCOPE (European Confederation of Pharmaceutical Entrepreneurs).

This talk is part of the Health Economics @ Cambridge series.

This talk is included in these lists:

• BHRU Annual Lecture 2015
• BHRU Annual Lecture 2016
• Cambridge Centre for Data-Driven Discovery (C2D3)
• Cambridge talks
• Cardiovascular Epidemiology Unit Special Seminars
• Chris Davis' list
• Clinical School - Seminar room 10
• Department of Public Health and Primary Care
• Health Economics @ Cambridge
• Interested Talks
• Primary Care
• PublicHealth@Cambridge
• Trust & Technology Initiative - interesting events
• bld31
• ndk22's list
• ob366-ai4er
• primary care
• rp587

Note that ex-directory lists are not shown.